[go: up one dir, main page]

AR016875A1 - Un amino-derivado que posee actividad neuronal, una composicion que lo contiene y usos de los mismos para estimular la actividad neuronal - Google Patents

Un amino-derivado que posee actividad neuronal, una composicion que lo contiene y usos de los mismos para estimular la actividad neuronal

Info

Publication number
AR016875A1
AR016875A1 ARP980104214A ARP980104214A AR016875A1 AR 016875 A1 AR016875 A1 AR 016875A1 AR P980104214 A ARP980104214 A AR P980104214A AR P980104214 A ARP980104214 A AR P980104214A AR 016875 A1 AR016875 A1 AR 016875A1
Authority
AR
Argentina
Prior art keywords
straight
branched
alkenyl
alkyl
alkynyl
Prior art date
Application number
ARP980104214A
Other languages
English (en)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25444494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR016875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR016875A1 publication Critical patent/AR016875A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente está relacionada con compuestos, métodos y composiciones farmacéuticas para la estimulacion del crecimiento de neuritas en células nerviosas.Los compuestos y las composiciones y métodos que los utilizan pueden ser usados solos o en conjunto con un factor neurotrofico, tal como el factor decrecimiento nervioso, para promover la reparacion de dano neuronal provocado por enfermedad o trauma físico. Un amino derivativo, caracterizado porqueresponde a la formula (I) y derivados farmacéuticamente aceptables del mismo, en el cual: A y B son seleccionados independientemene de hidrogeno, Ar, alquiloC1-6 de cadena recta o ramificada, alquenilo o alquinilo C2-6 de cadena recta o ramificada, alquilo C1-6 de cadena recta o ramificada sustituido conciclo-alquilo C5-7, alquenilo o alquinilo C2-6 de cadena recta o ramificada sustituido con ciclo-alquilo C5-7,alquilo C1-6 de cadena recta o ramificadasustituido con ciclo-alquenilo C5-7, alquenilo o alquinilo C2-6 de cadena recta o ramificadasustituido con ciclo-alquenilo C5-7, alquilo C1-6 de cadena rectao ramificada sustituido con Ar, alquenilo o alquinilo C2-6 de cadena recta o ramificada sustituido con Ar, en donde cualquiera de los grupos CH2 dedichas cadenas alquinil, alquenilo oalquilo en A o B es reemplazado opcionalmente por O, S, S(O), S(O)2 o N(R); en donde: R es seleccionado de hidrogeno,alquilo C1-6 de cadena recta o ramificada, o alquenilo o alquinilo C2-6 de cadena recta o ramificada; Ar es seleccionado de fenilo, 1-naftilo, 2-naftilo,indenilo, azulenilo, fluorenilo, antracenilo, 2-furilo, 3-furilo, 2-tienilo, 3-tienilo, 2-piridilo, 3-piridilo, 4-piridilo, pirrolilo, oxazolilo, tiazolilo,imidazolilo, piraxolilo, 2-pirazolinilo, pirazolidinilo, isoxazolilo, isotiazolilo, 1,2,3-oxadiazolilo, 2-pirazolinilo, pirazolidinilo, isoxazolilo,isotiazolilo, 1,2,3-oxadiazolilo, 1,2,3-triazolilo, 1,3,4-tiadiazolilo, 1,2,3 tiadiazolilo, 1,2,4-triazolilo, 1,2,4-oxadiazolilo, 1,2,4-tiadiazolilo,benzoxazolilo, piridacinilo, pirimidinilo, piracinilo, 1,3,5-triazinilo, 1,3,5-tritianilo, indolizinilo, indolilo, isoindolilo, 3H-indolilo, indolinilo,
ARP980104214A 1997-08-29 1998-08-25 Un amino-derivado que posee actividad neuronal, una composicion que lo contiene y usos de los mismos para estimular la actividad neuronal AR016875A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92083897A 1997-08-29 1997-08-29
US09/085,441 US6268384B1 (en) 1997-08-29 1998-05-27 Compounds possessing neuronal activity

Publications (1)

Publication Number Publication Date
AR016875A1 true AR016875A1 (es) 2001-08-01

Family

ID=25444494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104214A AR016875A1 (es) 1997-08-29 1998-08-25 Un amino-derivado que posee actividad neuronal, una composicion que lo contiene y usos de los mismos para estimular la actividad neuronal

Country Status (7)

Country Link
US (1) US6268384B1 (es)
JP (1) JP2010100643A (es)
KR (1) KR100859758B1 (es)
AR (1) AR016875A1 (es)
CO (2) CO5080734A1 (es)
IL (1) IL134536A (es)
ZA (1) ZA987478B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010052503A (ko) 1998-06-03 2001-06-25 다니엘 피. 맥컬럼 Ｎ-헤테로사이클릭 카복실산 또는 카복실산 등입체의ｎ-결합된 설폰아미드
JP2003503500A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 神経学的疾患の治療のためのキヌクリジン誘導体
US6399606B1 (en) * 1999-11-29 2002-06-04 Nippon Kayaku Co., Ltd. Neuroprotective agents and methods related thereto
US20030171411A1 (en) * 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
US6952925B2 (en) * 2002-04-17 2005-10-11 SME Associates, Inc. Optimizing inlet air for gas turbines
WO2004002481A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
RU2386622C9 (ru) 2004-01-06 2021-04-21 Ново Нордиск А/С Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
US7777042B2 (en) * 2004-06-29 2010-08-17 Aventis Pharmaceuticals Inc. N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof
EP1778637B1 (en) 2004-06-29 2012-02-22 Aventis Pharmaceuticals Inc. FKBP-binding composition and pharmaceutical use thereof
ATE547396T1 (de) * 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
WO2007006760A1 (en) * 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
EP1904467B1 (en) * 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
EP2099777B1 (en) * 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
WO2012177893A2 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9845292B2 (en) 2013-09-19 2017-12-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Selective FKBP51 ligands for treatment of psychiatric disorders
US20170226059A1 (en) * 2014-08-19 2017-08-10 Barbara Jagodzinska Apoe4-targeted theraputics that increase sirt1
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
IL115685A (en) 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds

Also Published As

Publication number Publication date
KR100859758B1 (ko) 2008-09-24
US6268384B1 (en) 2001-07-31
CO5080734A1 (es) 2001-09-25
JP2010100643A (ja) 2010-05-06
KR20010023413A (ko) 2001-03-26
ZA987478B (en) 1999-02-22
CO5080732A1 (es) 2001-09-25
IL134536A (en) 2006-08-20

Similar Documents

Publication Publication Date Title
AR016875A1 (es) Un amino-derivado que posee actividad neuronal, una composicion que lo contiene y usos de los mismos para estimular la actividad neuronal
ECSP21056710A (es) Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
US6194440B1 (en) Small molecule carbamate or urea hair growth compositions and uses
AR013873A1 (es) Una composicion que comprende derivados de tetralina y factores ico neurologicos para estimular el crecimiento de neuritas en celulas nerviosas
AR011278A1 (es) Una composicion y un medicamento que comprenden derivados amino acidos y un factor neutrofico para estimular el crecimiento de neuritas en celulasnerviosas
RU94046306A (ru) Производные индолокарбазолимида, смесь их изомеров или отдельные изомеры и их соли и фармацевтическая композиция с активностью, ингибирующей протеинкиназу с или киназу легкой миозиновой цепи или подавляющей иммунные реакции
UY26464A1 (es) " compuestos, composiciones y métodos para estimular el crecimiento y elongación de neuronas"
ES2103506T3 (es) Utilizacion de acidos hidroxicarboxilicos y sus derivados para la preparacion de composiciones dermatologicas topicas para el tratamiento de arrugas.
RU2001120374A (ru) Композиции для ухода за кожей, содержащие цис-9, транс-11 линолевую кислоту
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
NZ335396A (en) Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors
MX9304547A (es) Derivados 1-piperazinil-n-fenilacetamida de 4,5-difenil-oxazoles, tiazoles e imidazoles, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.
BR0310087A (pt) Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
ES2177593T3 (es) Formulaciones que contienen esculosido y uso de las mismas en los campos farmaceutico y cosmetico.
ITMI941497A1 (it) Combinazioni di sostanze vasoattive con acidi grassi per combattere la caduta dei capelli
PE20040961A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
AR029229A1 (es) Compuestos de piperazina sustituida, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento
ATE482230T1 (de) Peptide, die bei der linderung von hautleiden oder der behandlung von periodentalkrankheiten wirkung zeigen
CZ289293A3 (en) Preparation for preventing or reduction of alopecia induced by chemotherapy
ECSP014108A (es) Procedimiento para la fabricacion de una forma farmaceutica semisolida conteniendo dexketoprofeno trometamol y su utilizacion en el tratamiento topico de la inflamacion
EP1083875A1 (en) Small molecule carbamate or urea hair growth compositions and uses
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ES2067206T3 (es) Composiciones farmaceuticas conteniendo 3-amino-epsilon-caprolactamas para estimular el proceso de aprendizaje y la memoria.
KR102107808B1 (ko) 기억력 및 인지기능 개선용 펩타이드

Legal Events

Date Code Title Description
FB Suspension of granting procedure